Review




Structured Review

Pfizer Inc otenabant (cp-945598)
Update of major metabolic targets and potential monotherapy drugs under development for NAFLD/NASH
Otenabant (Cp 945598), supplied by Pfizer Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cp-945598/cp+945+598/pmc10531241-138-1-17
Average 90 stars, based on 1 article reviews
otenabant (cp-945598) - by Bioz Stars, 2026-11
90/100 stars

Images

1) Product Images from "Overview and prospect of NAFLD: Significant roles of nutrients and dietary patterns in its progression or prevention"

Article Title: Overview and prospect of NAFLD: Significant roles of nutrients and dietary patterns in its progression or prevention

Journal: Hepatology Communications

doi: 10.1097/HC9.0000000000000234

Update of major metabolic targets and potential monotherapy drugs under development for NAFLD/NASH
Figure Legend Snippet: Update of major metabolic targets and potential monotherapy drugs under development for NAFLD/NASH

Techniques Used:

Related Articles

other:

Article Title: Glucokinase activators and methods of using same
Article Snippet: Examples of suitable anti-obesity agents for use in combination with the compound of the present invention include a cannabinoid receptor 1 antagonist or inverse agonist (e.g., rimonabant, (4S)-3-(4-chlorophenyl)-N-[(4-chlorophenyl)sulfonyl]-4,5-dihydro-N′-methyl-4-phenyl-1H-pyrazole-1-carboximidamide (SLV 319), CP-945598 (Pfizer), Surinabant (SR-147778, Sanofi-Aventis), N-[(1S,2S)-3-(4-chlorophenyl)-2-(3-cyanophenyl)-1-methylpropyl]-2-methyl-2-{[5-(trifluoromethyl)pyridin-2-yl]oxy}propanamide (Merck) and those discussed in Hertzog, D. L., Expert Opin.

Article Title: Pyrimidinylpiperidinyloxypyridone analogues as GPR119 modulators
Article Snippet: 5,612,359 and 6,043,265), Dual ET/AII antagonist (e.g., compounds disclosed in WO 00/01389), neutral endopeptidase (NEP) inhibitors, vasopeptidase inhibitors (dual NEP-ACE inhibitors) (e.g., omapatrilat and gemopatrilat), nitrates, central alpha agonists (e.g., clonidine), alpha1 blockers (e.g., prazosine), arterial vasodilators (e.g., minoxidil), sympatolytics (e.g., resperine), renin inhibitors (e.g., Aliskiren (Novartis)).

Article Title: [6,5]—bicyclic GPR119 G protein-coupled receptor agonists
Article Snippet: Examples of suitable anti-obesity agents for use in combination with the compounds of the present invention include a cannabinoid receptor 1 antagonist or inverse agonist (e.g., rimonabant, (4S)-3-(4-chlorophenyl)-N-[(4-chlorophenyl)sulfonyl]-4,5-dihydro-N′-methyl-4-phenyl-1H-Pyrazole-1-carboximidamide (SLV 319), CP-945598 (Pfizer), Surinabant (SR-147778, Sanofi-Aventis), N-[(1S,2S)-3-(4-Chlorophenyl)-2-(3-cyanophenyl)-1-methylpropyl]-2-methyl-2-{[5-(trifluoromethyl)pyridin-2-yl]oxy}propanamide (Merck) and those discussed in Hertzog, D. L., Expert Opin.

Article Title: Substituted [1,2,4]triazolo[4,3-A]pyrazine 11-beta-hydroxysteroid dehydrogenase inhibitors
Article Snippet: Cannabinoid receptor I antagonists and inverse agonists which may be optionally employed in combination with compounds of the present invention include rimonabant, SLV 319, CP-945598 (Pfizer), SR-147778 (Sanofi-Aventis), MK0364 (Merck) and those discussed in Hertzog, D. L., Expert Opin.

Article Title: Pyridone GPR119 G protein-coupled receptor agonists
Article Snippet: Examples of suitable anti-obesity agents for use in combination with the compounds of the present invention include a cannabinoid receptor 1 antagonist or inverse agonist (e.g., rimonabant, (4S)-3-(4-chlorophenyl)-N-[(4-chlorophenyl)sulfonyl]-4,5-dihydro-N′-methyl-4-phenyl-1H-Pyrazole-1-carboximidamide (SLV 319), CP-945598 (Pfizer), Surinabant (SR-147778, Sanofi-Aventis), N-[(1S,2S)-3-(4-Chlorophenyl)-2-(3-cyanophenyl)-1-methylpropyl]-2-methyl-2-{[5-(trifluoromethyl)pyridin-2-yl]oxy}propanamide (Merck) and those discussed in Hertzog, D. L., Expert Opin.

Article Title: Bicyclic nitrogen containing heteroaryl TGR5 receptor modulators
Article Snippet: Patents, 14:1435-1452 (2004)); a beta 3 adrenergic agonist (e.g., rafabegron (AJ9677, Takeda/Dainippon), N-[4-[2-[[(2S)-3-[(6-amino-3-pyridinyl)oxy]-2-hydroxypropyl]amino]ethyl]phenyl]-4-(1-methylethyl)-benzenesulfonamide (L750355, Merck), or CP331648 (Pfizer), or other known beta 3 agonists, as disclosed in U.S. Pat.

Article Title: Bicyclic heteroaryl compounds as GPR119 modulators
Article Snippet: Examples of suitable anti-obesity agents for use in combination with the compounds of the present invention include a cannabinoid receptor 1 antagonist or inverse agonist (e.g., rimonabant, (4S)-3-(4-chlorophenyl)-N-[(4-chlorophenyl)sulfonyl]-4,5-dihydro-N′-methyl-4-phenyl-1H-pyrazole-1-carboximidamide (SLV 319), CP-945598 (Pfizer), Surinabant (SR-147778, Sanofi-Aventis), N-[(1S,2S)-3-(4-chlorophenyl)-2-(3-cyanophenyl)-1-methylpropyl]-2-methyl-2-{[5-(trifluoromethyl)pyridin-2-yl]oxy}propanamide (Merck) and those discussed in Hertzog, D. L., Expert Opin.

Article Title: Therapeutic peptides
Article Snippet: Combinations together with the following compounds are also contemplated as embodiments of the current invention: Astra ZenecA AZD4076, Enanta EDP-305, Galectin Therapeutics GR-MD-02, gemcabene, Gilead GS-0976, Gilead GS-9674, Merck MK-4074, pioglitazone, Pfizer PF-06835919, Pfizer CP-945598, Astellas ASP9831, Boehringer Ingelheim BI 1467335, Bristol Myers Squibb BMS-986036, avandia, metformin, losartan, Can-Fite CF102, pentoxifylline, solithromycin, Cirius MSDC-0602K, emricasan, Conatus IDN-6556, metreleptin, aramchol, Genfit GFT505, simtuzumab, Gilead GS-4997, Gilead GS-9450, Roche TR019622, Roche R05093151, Immuron IMM-124E, obeticholic acid, Inventiva IVA337, Madrigal MGL-3196, MN-001, Mitsubishi Tanabe MT-3995, Mochida EPA-E, NGM Biopharma NGM282, Novartis LMB763, Novartis LJN452, Shire SHP626, cenicriviroc, liraglutide, and saroglitazar.



Similar Products

90
Bio-Techne corporation il 1β
Il 1β, supplied by Bio-Techne corporation, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cp-945598/CP+945598+hydrochloride/10__4236_slash_jcdsa__2022__122009-47-12-37
Average 90 stars, based on 1 article reviews
il 1β - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

94
MedChemExpress cp 945598 hcl otenabant
Cp 945598 Hcl Otenabant, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cp-945598/Otenabant/bio_rxiv__64898__2026__04__28__720360-35-0-9
Average 94 stars, based on 1 article reviews
cp 945598 hcl otenabant - by Bioz Stars, 2026-11
94/100 stars
  Buy from Supplier

90
STEMCELL Technologies Inc cp-945598
Cp 945598, supplied by STEMCELL Technologies Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cp-945598/cp+945598/pmc10500295-25-0-4
Average 90 stars, based on 1 article reviews
cp-945598 - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

90
Pfizer Inc otenabant (cp-945598)
Update of major metabolic targets and potential monotherapy drugs under development for NAFLD/NASH
Otenabant (Cp 945598), supplied by Pfizer Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cp-945598/cp+945+598/pmc10531241-138-1-17
Average 90 stars, based on 1 article reviews
otenabant (cp-945598) - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

90
Pfizer Inc cp-945598
Update of major metabolic targets and potential monotherapy drugs under development for NAFLD/NASH
Cp 945598, supplied by Pfizer Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cp-945598/cp+945598/us11332497-1130-34-33
Average 90 stars, based on 1 article reviews
cp-945598 - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

90
Tocris cp 945598 hydrochloride
Update of major metabolic targets and potential monotherapy drugs under development for NAFLD/NASH
Cp 945598 Hydrochloride, supplied by Tocris, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cp-945598/CP+945598+hydrochloride/pm33931733-269-38-43
Average 90 stars, based on 1 article reviews
cp 945598 hydrochloride - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

90
Bio-Techne corporation cp 945598 hydrochloride
Update of major metabolic targets and potential monotherapy drugs under development for NAFLD/NASH
Cp 945598 Hydrochloride, supplied by Bio-Techne corporation, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cp-945598/CP+945598+hydrochloride/custom%404236%4010%2E7554%2Felife%2E33892
Average 90 stars, based on 1 article reviews
cp 945598 hydrochloride - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

90
Tocris cp945598 hydrochloride
( A ) Left: example traces of evoked EPSCs from one VTA DA neuron during baseline and following 5 μM CB1R agonist WIN55212-2 application. Right: summary data for EPSC amplitude over time, normalized to baseline. ( B ) Left: example traces of evoked EPSCs from one VTA DA neuron during baseline and following 1 μM oxytocin application in the presence of CB1R agonist WIN55212-2. Right: summary data for EPSC amplitude over time, normalized to baseline. ( C ) Same as ( B ), but in the presence of CB1R inverse agonist AM251. ( D ) Same as ( B ), but in the presence of orlistat (THL), a blocker of 2-AG synthesizing enzyme diacylglycerol lipase α (DGLα). ( E ) Same as ( B ), but with THL in the internal solution to block 2-AG synthesis. ( F ) Same as ( B ), but with U73122 in the internal solution to inhibit PLC activity. ( G ) Summary data for EPSC amplitude changes induced by CB1R agonist WIN55212-2 and oxytocin in the presence of WIN55212-2, CB1R inverse agonist AM251, CB1R antagonist <t>CP945598,</t> orlistat (THL), intracellular THL, and intracellular U73122, separately. **p<0.01, Wilcoxon signed rank test vs. baseline. For each condition respectively, n = 7 neurons from five mice, six neurons from four mice, six neurons from three mice, six neurons from four mice, six neurons from four mice, seven neurons from four mice, and seven neurons from four mice. Error bars reflect SEM. ( H ) Schematic summary of the mechanism underlying direct oxytocinergic regulation of excitatory synaptic transmission in VTA DA neurons. Oxytocin binds to G q -coupled OxtR, activating the phospholipase C (PLC) pathway. PLC cleaves phosphatidylinositol 1,4,5-bisphosphate into diacylglycerol (DAG) and inositol 1,4,5-trisphosphate, and DAG is subsequently converted into 2-AG by DAG lipase (DGL). 2-AG released by VTA DA neurons binds to presynaptic G i/o -coupled CB1R, decreasing glutamate release. 10.7554/eLife.33892.013 Figure 3—source data 1. Summary tables of evoked EPSC amplitudes in response to endocannabinoid-signaling related pharmacological agents.
Cp945598 Hydrochloride, supplied by Tocris, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cp-945598/CP+945598+hydrochloride/pmc05910020-22-4-7
Average 90 stars, based on 1 article reviews
cp945598 hydrochloride - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

93
Tocris drug cp945598 hydrochloride tocris
Figure 3. Retrograde endocannabinoid signaling underlies oxytocinergic modulation of excitatory synaptic transmission. (A) Left: example traces of evoked EPSCs from one VTA DA neuron during baseline and following 5 mM CB1R agonist WIN55212-2 application. Right: summary data for EPSC amplitude over time, normalized to baseline. (B) Left: example traces of evoked EPSCs from one VTA DA neuron during baseline and following 1 mM oxytocin application in the presence of CB1R agonist WIN55212-2. Right: summary data for EPSC amplitude over time, normalized to baseline. (C) Same as (B), but in the presence of CB1R inverse agonist AM251. (D) Same as (B), but in the presence of orlistat (THL), a blocker of 2-AG synthesizing enzyme diacylglycerol lipase a (DGLa). (E) Same as (B), but with THL in the internal solution to block 2-AG synthesis. (F) Same as (B), but with U73122 in the internal solution to inhibit PLC activity. (G) Summary data for EPSC amplitude changes induced by CB1R agonist WIN55212-2 and oxytocin in the presence of WIN55212-2, CB1R inverse agonist AM251, CB1R antagonist <t>CP945598,</t> orlistat (THL), intracellular THL, and intracellular U73122, separately. **p<0.01, Wilcoxon signed rank Figure 3 continued on next page
Drug Cp945598 Hydrochloride Tocris, supplied by Tocris, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cp-945598/CP+945598+hydrochloride/10__7554_slash_elife__33892-280-64-67
Average 93 stars, based on 1 article reviews
drug cp945598 hydrochloride tocris - by Bioz Stars, 2026-11
93/100 stars
  Buy from Supplier

Image Search Results


Update of major metabolic targets and potential monotherapy drugs under development for NAFLD/NASH

Journal: Hepatology Communications

Article Title: Overview and prospect of NAFLD: Significant roles of nutrients and dietary patterns in its progression or prevention

doi: 10.1097/HC9.0000000000000234

Figure Lengend Snippet: Update of major metabolic targets and potential monotherapy drugs under development for NAFLD/NASH

Article Snippet: , Otenabant (CP-945598) , Phase 1 , NASH , √ , NA , NA , NA , Pfizer , Aronne et al .

Techniques:

( A ) Left: example traces of evoked EPSCs from one VTA DA neuron during baseline and following 5 μM CB1R agonist WIN55212-2 application. Right: summary data for EPSC amplitude over time, normalized to baseline. ( B ) Left: example traces of evoked EPSCs from one VTA DA neuron during baseline and following 1 μM oxytocin application in the presence of CB1R agonist WIN55212-2. Right: summary data for EPSC amplitude over time, normalized to baseline. ( C ) Same as ( B ), but in the presence of CB1R inverse agonist AM251. ( D ) Same as ( B ), but in the presence of orlistat (THL), a blocker of 2-AG synthesizing enzyme diacylglycerol lipase α (DGLα). ( E ) Same as ( B ), but with THL in the internal solution to block 2-AG synthesis. ( F ) Same as ( B ), but with U73122 in the internal solution to inhibit PLC activity. ( G ) Summary data for EPSC amplitude changes induced by CB1R agonist WIN55212-2 and oxytocin in the presence of WIN55212-2, CB1R inverse agonist AM251, CB1R antagonist CP945598, orlistat (THL), intracellular THL, and intracellular U73122, separately. **p<0.01, Wilcoxon signed rank test vs. baseline. For each condition respectively, n = 7 neurons from five mice, six neurons from four mice, six neurons from three mice, six neurons from four mice, six neurons from four mice, seven neurons from four mice, and seven neurons from four mice. Error bars reflect SEM. ( H ) Schematic summary of the mechanism underlying direct oxytocinergic regulation of excitatory synaptic transmission in VTA DA neurons. Oxytocin binds to G q -coupled OxtR, activating the phospholipase C (PLC) pathway. PLC cleaves phosphatidylinositol 1,4,5-bisphosphate into diacylglycerol (DAG) and inositol 1,4,5-trisphosphate, and DAG is subsequently converted into 2-AG by DAG lipase (DGL). 2-AG released by VTA DA neurons binds to presynaptic G i/o -coupled CB1R, decreasing glutamate release. 10.7554/eLife.33892.013 Figure 3—source data 1. Summary tables of evoked EPSC amplitudes in response to endocannabinoid-signaling related pharmacological agents.

Journal: eLife

Article Title: Oxytocin functions as a spatiotemporal filter for excitatory synaptic inputs to VTA dopamine neurons

doi: 10.7554/eLife.33892

Figure Lengend Snippet: ( A ) Left: example traces of evoked EPSCs from one VTA DA neuron during baseline and following 5 μM CB1R agonist WIN55212-2 application. Right: summary data for EPSC amplitude over time, normalized to baseline. ( B ) Left: example traces of evoked EPSCs from one VTA DA neuron during baseline and following 1 μM oxytocin application in the presence of CB1R agonist WIN55212-2. Right: summary data for EPSC amplitude over time, normalized to baseline. ( C ) Same as ( B ), but in the presence of CB1R inverse agonist AM251. ( D ) Same as ( B ), but in the presence of orlistat (THL), a blocker of 2-AG synthesizing enzyme diacylglycerol lipase α (DGLα). ( E ) Same as ( B ), but with THL in the internal solution to block 2-AG synthesis. ( F ) Same as ( B ), but with U73122 in the internal solution to inhibit PLC activity. ( G ) Summary data for EPSC amplitude changes induced by CB1R agonist WIN55212-2 and oxytocin in the presence of WIN55212-2, CB1R inverse agonist AM251, CB1R antagonist CP945598, orlistat (THL), intracellular THL, and intracellular U73122, separately. **p<0.01, Wilcoxon signed rank test vs. baseline. For each condition respectively, n = 7 neurons from five mice, six neurons from four mice, six neurons from three mice, six neurons from four mice, six neurons from four mice, seven neurons from four mice, and seven neurons from four mice. Error bars reflect SEM. ( H ) Schematic summary of the mechanism underlying direct oxytocinergic regulation of excitatory synaptic transmission in VTA DA neurons. Oxytocin binds to G q -coupled OxtR, activating the phospholipase C (PLC) pathway. PLC cleaves phosphatidylinositol 1,4,5-bisphosphate into diacylglycerol (DAG) and inositol 1,4,5-trisphosphate, and DAG is subsequently converted into 2-AG by DAG lipase (DGL). 2-AG released by VTA DA neurons binds to presynaptic G i/o -coupled CB1R, decreasing glutamate release. 10.7554/eLife.33892.013 Figure 3—source data 1. Summary tables of evoked EPSC amplitudes in response to endocannabinoid-signaling related pharmacological agents.

Article Snippet: chemical compound, drug , CP945598 hydrochloride , Tocris , Cat#4236; CAS 686347-12-6 , .

Techniques: Blocking Assay, Activity Assay, Transmission Assay

( A ) Left: example traces of evoked EPSCs from one VTA DA neuron during baseline and following 1 μM oxytocin application in the presence of CB1R antagonist CP945598. Right: summary data for EPSC amplitude over time, normalized to baseline. n = 6 neurons from four mice. ( B ) Summary results show paired-pulse ratio during baseline and following CB1R agonist WIN55212-2 application and oxytocin application in the presence of WIN55212-2, CB1R inverse agonist AM251, CB1R antagonist CP945598, and orlistat (THL), separately. **p<0.01, Wilcoxon matched-pairs signed rank test. For each condition respectively, n = 7 neurons from five mice, six neurons from four mice, six neurons from three mice, six neurons from four mice, six neurons from four mice, seven neurons from four mice, and six neurons from four mice. Error bars reflect SEM.

Journal: eLife

Article Title: Oxytocin functions as a spatiotemporal filter for excitatory synaptic inputs to VTA dopamine neurons

doi: 10.7554/eLife.33892

Figure Lengend Snippet: ( A ) Left: example traces of evoked EPSCs from one VTA DA neuron during baseline and following 1 μM oxytocin application in the presence of CB1R antagonist CP945598. Right: summary data for EPSC amplitude over time, normalized to baseline. n = 6 neurons from four mice. ( B ) Summary results show paired-pulse ratio during baseline and following CB1R agonist WIN55212-2 application and oxytocin application in the presence of WIN55212-2, CB1R inverse agonist AM251, CB1R antagonist CP945598, and orlistat (THL), separately. **p<0.01, Wilcoxon matched-pairs signed rank test. For each condition respectively, n = 7 neurons from five mice, six neurons from four mice, six neurons from three mice, six neurons from four mice, six neurons from four mice, seven neurons from four mice, and six neurons from four mice. Error bars reflect SEM.

Article Snippet: chemical compound, drug , CP945598 hydrochloride , Tocris , Cat#4236; CAS 686347-12-6 , .

Techniques:

Journal: eLife

Article Title: Oxytocin functions as a spatiotemporal filter for excitatory synaptic inputs to VTA dopamine neurons

doi: 10.7554/eLife.33892

Figure Lengend Snippet:

Article Snippet: chemical compound, drug , CP945598 hydrochloride , Tocris , Cat#4236; CAS 686347-12-6 , .

Techniques: Concentration Assay, Recombinant, RNAscope, Fluorescence, Multiplex Assay, Software

Figure 3. Retrograde endocannabinoid signaling underlies oxytocinergic modulation of excitatory synaptic transmission. (A) Left: example traces of evoked EPSCs from one VTA DA neuron during baseline and following 5 mM CB1R agonist WIN55212-2 application. Right: summary data for EPSC amplitude over time, normalized to baseline. (B) Left: example traces of evoked EPSCs from one VTA DA neuron during baseline and following 1 mM oxytocin application in the presence of CB1R agonist WIN55212-2. Right: summary data for EPSC amplitude over time, normalized to baseline. (C) Same as (B), but in the presence of CB1R inverse agonist AM251. (D) Same as (B), but in the presence of orlistat (THL), a blocker of 2-AG synthesizing enzyme diacylglycerol lipase a (DGLa). (E) Same as (B), but with THL in the internal solution to block 2-AG synthesis. (F) Same as (B), but with U73122 in the internal solution to inhibit PLC activity. (G) Summary data for EPSC amplitude changes induced by CB1R agonist WIN55212-2 and oxytocin in the presence of WIN55212-2, CB1R inverse agonist AM251, CB1R antagonist CP945598, orlistat (THL), intracellular THL, and intracellular U73122, separately. **p<0.01, Wilcoxon signed rank Figure 3 continued on next page

Journal: eLife

Article Title: Oxytocin functions as a spatiotemporal filter for excitatory synaptic inputs to VTA dopamine neurons

doi: 10.7554/elife.33892

Figure Lengend Snippet: Figure 3. Retrograde endocannabinoid signaling underlies oxytocinergic modulation of excitatory synaptic transmission. (A) Left: example traces of evoked EPSCs from one VTA DA neuron during baseline and following 5 mM CB1R agonist WIN55212-2 application. Right: summary data for EPSC amplitude over time, normalized to baseline. (B) Left: example traces of evoked EPSCs from one VTA DA neuron during baseline and following 1 mM oxytocin application in the presence of CB1R agonist WIN55212-2. Right: summary data for EPSC amplitude over time, normalized to baseline. (C) Same as (B), but in the presence of CB1R inverse agonist AM251. (D) Same as (B), but in the presence of orlistat (THL), a blocker of 2-AG synthesizing enzyme diacylglycerol lipase a (DGLa). (E) Same as (B), but with THL in the internal solution to block 2-AG synthesis. (F) Same as (B), but with U73122 in the internal solution to inhibit PLC activity. (G) Summary data for EPSC amplitude changes induced by CB1R agonist WIN55212-2 and oxytocin in the presence of WIN55212-2, CB1R inverse agonist AM251, CB1R antagonist CP945598, orlistat (THL), intracellular THL, and intracellular U73122, separately. **p<0.01, Wilcoxon signed rank Figure 3 continued on next page

Article Snippet: DOI: https://doi.org/10.7554/eLife.33892 17 of 26 Continued Reagent type (species) or resource Designation Source or reference Identifiers Additional information chemical compound, drug SR 49059 Tocris Cat#2310; CAS 150375-75-0 chemical compound, drug NBQX disodium salt Tocris Cat#1044; CAS 479347-86-9 chemical compound, drug (RS)-CPP Tocris Cat#0173; CAS 100828-16-8 chemical compound, drug SR95531 hydrobromide Tocris Cat#1262; CAS 104104-50-9 chemical compound, drug U73122 Tocris Cat#1268; CAS 112648-68-7 chemical compound, drug CP945598 hydrochloride Tocris Cat#4236; CAS 686347-12-6 chemical compound, drug WIN55212-2 Tocris Cat#1038; CAS 131543-23-2 chemical compound, drug AM251 Tocris Cat#1117; CAS 183232-66-8 chemical compound, drug orlistat (THL) Tocris Cat#3540; CAS 96829-58-2 chemical compound, drug MNI-L-glutamate Tocris Cat#1490; CAS 295325-62-1 chemical compound, drug Alexa Fluor 488 hydrazide Thermo Fisher Scientific Cat#A10436 chemical compound, drug Alexa Fluor 594 hydrazide Thermo Fisher Scientific Cat#A10438 chemical compound, drug Green retrobeads (GRB) Lumafluor Inc. Cat#G180 software, algorithm GraphPad Prizm 5 GraphPad RRID:SCR_002798 software, algorithm FIJI Schindelin et al., 2012 http://fiji.sc/; RRID:SCR_002285 software, algorithm MATLAB MathWorks RRID:SCR_001622 software, algorithm Igor Pro Wavemetrics RRID:SCR_000325 software, algorithm SPSS IBM RRID:SCR_002865

Techniques: Transmission Assay, Blocking Assay, Activity Assay